Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Sold by Decheng Capital LLC

Decheng Capital LLC lowered its stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 44.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 694,254 shares of the company's stock after selling 555,746 shares during the period. Phathom Pharmaceuticals comprises about 1.2% of Decheng Capital LLC's portfolio, making the stock its 16th largest holding. Decheng Capital LLC owned 1.02% of Phathom Pharmaceuticals worth $5,637,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Bank of New York Mellon Corp raised its stake in shares of Phathom Pharmaceuticals by 4.6% during the 4th quarter. Bank of New York Mellon Corp now owns 102,748 shares of the company's stock valued at $834,000 after buying an additional 4,557 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Phathom Pharmaceuticals by 21.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 25,641 shares of the company's stock valued at $209,000 after purchasing an additional 4,592 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Phathom Pharmaceuticals by 10.0% in the 4th quarter. Rhumbline Advisers now owns 55,968 shares of the company's stock valued at $454,000 after purchasing an additional 5,110 shares in the last quarter. MetLife Investment Management LLC increased its stake in shares of Phathom Pharmaceuticals by 28.0% in the 4th quarter. MetLife Investment Management LLC now owns 24,366 shares of the company's stock valued at $198,000 after purchasing an additional 5,337 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in shares of Phathom Pharmaceuticals by 41.3% in the 4th quarter. Wells Fargo & Company MN now owns 25,516 shares of the company's stock valued at $207,000 after purchasing an additional 7,462 shares in the last quarter. Hedge funds and other institutional investors own 99.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PHAT. HC Wainwright restated a "buy" rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. Cantor Fitzgerald upgraded Phathom Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, February 25th. Guggenheim restated a "buy" rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, April 2nd. Needham & Company LLC reiterated a "buy" rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Monday, April 21st. Finally, The Goldman Sachs Group cut their price objective on Phathom Pharmaceuticals from $12.00 to $10.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $21.83.

Phathom Pharmaceuticals Stock Up 1.0 %

Shares of Phathom Pharmaceuticals stock traded up $0.04 on Monday, hitting $4.15. 841,970 shares of the company were exchanged, compared to its average volume of 1,025,336. Phathom Pharmaceuticals, Inc. has a 1-year low of $3.81 and a 1-year high of $19.71. The stock has a market capitalization of $288.99 million, a price-to-earnings ratio of -0.73 and a beta of 0.35. The company has a 50-day moving average price of $5.11 and a 200 day moving average price of $8.05.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.